Key Points
- CFO Robert Stefanovich sold 38,700 shares on March 12 at about $7.76 (≈$300,312) and another 2,743 shares on March 16, leaving him with 255,701 shares — a 13.15% reduction in his position.
- CryoPort reported quarterly EPS of ($0.21), missing estimates by $0.02, while revenue of $45.45 million beat expectations, presenting mixed operational results.
- Analysts are mixed but the consensus is a Moderate Buy with an average price target of $12.94, and institutional investors own roughly 92.9% of the stock.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CFO Robert Stefanovich sold 2,743 shares of CryoPort stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $21,944.00. Following the transaction, the chief financial officer directly owned 280,371 shares in the company, valued at approximately $2,242,968. The trade was a 0.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Robert Stefanovich also recently made the following trade(s):
- On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The shares were sold at an average price of $7.76, for a total value of $300,312.00.
CryoPort Trading Up 2.3%
NASDAQ CYRX opened at $8.00 on Tuesday. The business has a fifty day simple moving average of $9.23 and a 200 day simple moving average of $9.36. CryoPort, Inc. has a 12 month low of $4.63 and a 12 month high of $11.45. The firm has a market capitalization of $398.88 million, a P/E ratio of 6.06 and a beta of 1.69.
CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The firm had revenue of $45.45 million for the quarter, compared to analysts' expectations of $42.92 million. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.
Hedge Funds Weigh In On CryoPort
Several institutional investors have recently added to or reduced their stakes in the stock. Basepoint Wealth LLC bought a new stake in CryoPort in the fourth quarter worth about $34,000. Tower Research Capital LLC TRC increased its stake in shares of CryoPort by 300.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after purchasing an additional 4,375 shares during the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CryoPort during the 3rd quarter worth approximately $53,000. ProShare Advisors LLC bought a new stake in shares of CryoPort in the 2nd quarter worth approximately $75,000. Finally, AlphaQuest LLC purchased a new position in CryoPort in the third quarter valued at approximately $79,000. Institutional investors own 92.90% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on CYRX. Wall Street Zen downgraded shares of CryoPort from a "hold" rating to a "sell" rating in a research report on Saturday, March 7th. Needham & Company LLC boosted their target price on CryoPort from $12.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of CryoPort in a report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.94.
Check Out Our Latest Stock Report on CryoPort
About CryoPort
(
Get Free Report)
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
